Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
The incretin hormones are intestinal polypeptides that enhance postprandial insulin secretion. Gastric inhibitory polypeptide (GIP) was initially thought to regulate gastric acid secretion, whereas glucagon-like peptide-1 (GLP-1) was discovered as a result of a systematic search for intestinal insulinotropic products of proglucagon gene expression. The incretin effect is markedly impaired or absent in patients with type 2 diabetes because of decreased secretion of GLP-1 and a loss of the insulinotropic effects of GIP. Metabolic control can be restored or greatly improved by administration of exogenous GLP-1, but this peptide is almost immediately degraded by dipeptidyl peptidase IV (DPP-IV), and therefore has little clinical value. DPP-IV-resistant analogues (incretin mimetics) have been identified or developed, and inhibitors of DPP-IV have also proved effective in protecting endogenous GLP-1 (and GIP) from degradation. Both principles have been tested in clinical studies. The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years. The DPP-IV inhibitors, given once or twice daily by mouth, also appear to provide lasting improvement in HbA(1)c, but are weight-neutral. The first incretin mimetic has reached the market in the US, and applications for approval of the first inhibitors are expected to be filed early in 2006.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The major effect of incretins is the potentiation of glucose-stimulated insulin secretion by pancreatic β-cells [14,15,16,17].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“controlled pivotal phase III studies involving 1,494 patients, in whom exenatide was given for 30 weeks as an add-on therapy to type 2 diabetic patients inadequately treated with sulfonylureas [68], metformin [69] or a combination of metformin and sulfonylureas [70].”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“In addition, GLP-1 was shown to inhibit appetite and food intake, both in healthy individuals [36], and in patients with type 2 diabetes [37].”
BackgroundSelf-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Research works printed but not linked: 4
- 26. Holst JJ, Orskov C, Schwartz TW, Buhl T, Baldissera F (1986) Proglucagon 78-107, a potent insulinotropic hormone from the lower small intestine. Diabetologia 29:549A (Abstract)
- 50. Larsen J, Jallad J, Damsbo P (1996) One-week continuous infusion of GLP-1(7-37) improves glycemic control in NIDDM. Diabetes 45:233A (Abstract)
- 54. Ehlers MRW, Roderick EH, Schneider RL, Kipnes MS (2002) Continuous subcutaneous infusion of recombinant GLP-1 for 7 days dose-dependently improved glycemic controls in type 2 diabetes. Diabetes 51:A579 (Abstract)
- 74. Nauck M, Hompesch M, Filipczak R et al (2004) Liraglutide as add-on to metformin in type 2 diabetes: significant improvement in glycaemic control with a reduction in body weight compared with glimepiride. Diabetologia 47:A281 (Abstract)
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Thomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Laferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Pathogenesis of Type 2 Diabetes Mellitus
Leahy, J. L. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.003 · Cited by 469
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
Sonne, D. P., Engstrøm, T., & Treiman, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.001 · Cited by 294
GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity
Overton, H. A., Fyfe, M. C. T., & Reynet, C. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707529 · Cited by 264
Preservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244
Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232
Glucagon-Like Peptide 1 Secretion by the L-Cell
Lim, G. E., & Brubaker, P. L. (2006) · Diabetes · doi:10.2337/db06-s020 · Cited by 223
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.024 · Cited by 223
Park, C. W., Kim, H. W., Ko, S. H., Lim, J. H., Ryu, G. R., Chung, H. W., Han, S. W., Shin, S. J., Bang, B. K., Breyer, M. D., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070778 · Cited by 218
Ahrén, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.005 · Cited by 204
Incretin and islet hormonal responses to fat and protein ingestion in healthy men
Carr, R. D., Larsen, M. O., Winzell, M. S., Jelic, K., Lindgren, O., Deacon, C. F., & Ahrén, B. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90233.2008 · Cited by 200
Minireview: The Wnt Signaling Pathway Effector TCF7L2 and Type 2 Diabetes Mellitus
Jin, T., & Liu, L. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0135 · Cited by 188
Suarez-Pinzon, W. L., Power, R. F., Yan, Y., Wasserfall, C., Atkinson, M., & Rabinovitch, A. (2008) · Diabetes · doi:10.2337/db08-0688 · Cited by 187
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
Gautier, J.-F., Choukem, S.-P., & Girard, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73397-4 · Cited by 183
Perry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K., Mattison, J. A., & Greig, N. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 182
Dipeptidyl peptidase-4: A key player in chronic liver disease
Itou, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i15.2298 · Cited by 177
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
Self-citationRole of Fat Hydrolysis in Regulating Glucagon-Like Peptide-1 Secretion
Beglinger, S., Drewe, J., Schirra, J., Göke, B., D'Amato, M., & Beglinger, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1062 · Cited by 146
Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · Diabetes Care · doi:10.2337/dc11-s221 · Cited by 147
Exercise therapy in Type 2 diabetes
Praet, S. F. E., & van Loon, L. J. C. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0129-0 · Cited by 128
The Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154
Vrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 153
New Drugs for Type 2 Diabetes Mellitus: What is their Place in Therapy?
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 141
Incretin hormone mimetics and analogues in diabetes therapeutics
Green, B. D., & Flatt, P. R. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.003 · Cited by 125
Giaccari, A., Sorice, G. P., & Muscogiuri, G. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.018 · Cited by 121
Treatment approach to type 2 diabetes: Past, present and future
Blaslov, K., Naranđa, F. S., Kruljac, I., & Renar, I. P. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i12.209 · Cited by 113
Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?
Heine, R. J., Diamant, M., Mbanya, J.-C., & Nathan, D. M. (2006) · BMJ · doi:10.1136/bmj.39022.462546.80 · Cited by 100
Wiederkehr, A., & Wollheim, C. B. (2008) · Cell Calcium · doi:10.1016/j.ceca.2007.11.004 · Cited by 101
Deane, A. M., Chapman, M. J., Fraser, R. J. L., Summers, M. J., Zaknic, A. V., Storey, J. P., Jones, K. L., Rayner, C. K., & Horowitz, M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d9d87a · Cited by 104
The Obesity Epidemic: Current and Future Pharmacological Treatments
Hofbauer, K. G., Nicholson, J. R., & Boss, O. (2006) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105256 · Cited by 104
Heile, A., Wallrapp, C., Klinge, P. M., Samii, A., Kassem, M. S., Silverberg, G. D., & Brinker, T. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.07.071 · Cited by 103
Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line
Simpson, A. K., Ward, P. S., Wong, K. Y., Collord, G. J., Habib, A. M., Reimann, F., & Gribble, F. M. (2007) · Diabetologia · doi:10.1007/s00125-007-0750-9 · Cited by 88
Mechanisms underlying proglucagon gene expression
Jin, T. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0085 · Cited by 91
Kanat, M., DeFronzo, R. A., & Abdul-Ghani, M. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i12.1207 · Cited by 82
Effect of gastric bypass surgery on the incretins
Laferrère, B. (2009) · Diabetes & Metabolism · doi:10.1016/s1262-3636(09)73458-5 · Cited by 90
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 83
Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
History of current non-insulin medications for diabetes mellitus
Quianzon, C. C. L., & Cheikh, I. E. (2012) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v2i3.19081 · Cited by 96
The role of oxyntomodulin and peptide tyrosine–tyrosine (PYY) in appetite control
Wynne, K., & Bloom, S. R. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0318 · Cited by 96
Diabetes remission after bariatric surgery: is it just the incretins?
Laferrère, B. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.143 · Cited by 88
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91
Jin, H. Y., Liu, W. J., Park, J. H., Baek, H. S., & Park, T. S. (2009) · Archives of Medical Research · doi:10.1016/j.arcmed.2009.09.005 · Cited by 94
Wang, Z. Q., Cefalu, W. T., Zhang, X. H., Yu, Y., Qin, J., Son, L., Rogers, P. M., Mashtalir, N., Bordelon, J. R., Ye, J., et al. (2008) · Diabetes · doi:10.2337/db07-1313 · Cited by 94
Kirino, Y., Sato, Y., Kamimoto, T., Kawazoe, K., Minakuchi, K., & Nakahori, Y. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0424 · Cited by 92
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Flatt, P. R. (2008) · Frontiers in bioscience · doi:10.2741/2956 · Cited by 89
Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes
Gallwitz, B. (2009) · Diabetes Care · doi:10.2337/dc09-s331 · Cited by 72
Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor
Willard, F. S., Bueno, A. B., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/709893 · Cited by 81
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
Yu, Z., & Jin, T. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.09.032 · Cited by 80
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Self-citationPathophysiology of diabetes mellitus type 2: beyond the duo "insulin resistance-secretion deficit".
Boada, C. A. C., & Martínez-Moreno, J. M. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6717 · Cited by 79
Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity
Mapelli, C., Natarajan, S. I., Meyer, J.-P., Bastos, M. M., Bernatowicz, M. S., Lee, V. G., Pluscec, J., Riexinger, D. J., Sieber-McMaster, E. S., Constantine, K. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900752a · Cited by 74
Norsa, L., Goulet, O., Alberti, D., DeKooning, B., Domellöf, M., Haiden, N., Hill, S. M., Indrio, F., Köglmeier, J., Lapillonne, A., et al. (2023) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003849 · Cited by 71
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Abasheva, D., Ortíz, A., & Fernández‐Fernández, B. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae296 · Cited by 70
GLP-1 and type 2 diabetes: physiology and new clinical advances
Combettes, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.003 · Cited by 69
Davies, M. J., Kela, R., & Khunti, K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 66
GALLWITZ, B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01196.x · Cited by 63
Harris, K. B., & McCarty, D. J. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814558242 · Cited by 57
Controlled release of biologics for the treatment of type 2 diabetes
Gilroy, C. A., Luginbuhl, K. M., & Chilkoti, A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.002 · Cited by 68
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Li, A., Su, X., Hu, S., & Wang, Y. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110605 · Cited by 49
Shao, W., Wang, Z., Ip, W., Chiang, Y.-T., Xiong, X., Chai, T., Xu, C., Wang, Q., & Jin, T. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00600.2012 · Cited by 58
Xu, F., Corley, E. G., Zacuto, M. J., Conlon, D. A., Pipik, B., Humphrey, G. R., Murry, J. A., & Tschaen, D. M. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo902573q · Cited by 61
Li, S., Xu, H., Cui, S., Wu, F., Zhang, Y., Su, M., Gong, Y.-H., Qiu, S., Jiao, Q., Qin, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00505 · Cited by 61
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
Jespersen, M. J., Knop, F. K., & Christensen, M. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.731394 · Cited by 57
Do we really know why diabetes remits after gastric bypass surgery?
Laferrère, B. (2011) · Endocrine · doi:10.1007/s12020-011-9514-x · Cited by 52
Göke, B. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01686.x · Cited by 58
Drug-Induced Endocrine and Metabolic Disorders
Ronald, C. W., Kong, A. P. S., Chan, N. N., Tong, P. C. Y., & Chan, J. C. N. (2007) · Drug Safety · doi:10.2165/00002018-200730030-00005 · Cited by 57
Cefalu, W. T., Waldman, S. A., & Ryder, S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100156 · Cited by 58
GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity
Fyfe, M. C. T., McCormack, J. G., Overton, H. A., Procter, M. J., & Reynet, C. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.4.403 · Cited by 55
Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.525 · Cited by 54
Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
Ishibashi, Y., Matsui, T., Ojima, A., Nishino, Y., Nakashima, S., Maeda, S., & Yamagishi, S. (2012) · Microvascular Research · doi:10.1016/j.mvr.2012.06.008 · Cited by 53
Scheen, A. J. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2006.11.005 · Cited by 52
Semaglutide seems to be more effective the other GLP-1Ras
Holst, J. J., & Madsbad, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.10 · Cited by 45
Self-citationPörksen, S., Nielsen, L. B., Kaas, A., Kocova, M., Chiarelli, F., Ørskov, C., Holst, J. J., Ploug, K. B., Hougaard, P., Hansen, L., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0244 · Cited by 50
Self-citationMechanism of the beneficial and protective effects of exenatide in diabetic rats
Lotfy, M. A., Singh, J., Rashed, H., Tariq, S., Zilahi, E., & Adeghate, E. A. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0426 · Cited by 51
Itou, M., Kawaguchi, T., Taniguchi, E., Sumie, S., Oriishi, T., Mitsuyama, K., Tsuruta, O., Ueno, T., & Sata, M. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05183.x · Cited by 50
Heile, A., & Brinker, T. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/aheile · Cited by 49
Hsu, W., Sue, S.-P., Liang, H., Tseng, C.-W., Lin, H.-C., Wen, W., & Lee, M. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.711723 · Cited by 49
An ‘Ayurveda-Biology’ platform for integrative diabetes management
Thottappillil, A., Kouser, S., Kukkupuni, S. K., & Vishnuprasad, C. N. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113575 · Cited by 46
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 49
Self-citationRamesh, N., Mortazavi, S., & Unniappan, S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.100 · Cited by 45
Yamamoto, K., Amako, M., Yamamoto, Y., Tsuchihara, T., Nukada, H., Yoshihara, Y., Arino, H., Fujita, M., Uenoyama, M., Tachibana, S., et al. (2013) · BioMed Research International · doi:10.1155/2013/315848 · Cited by 44
Pharmacological management of metabolic syndrome and its lipid complications.
Marvasti, T. B., & Adeli, K. (2010) · PubMed Central · Cited by 43
Analysis of glucagon-like peptide 1; what to measure?
Heijboer, A. C., Frans, A., Lomecky, M. Z., & Blankenstein, M. A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.03.010 · Cited by 47
Zheng, D., Ionut, V., Mooradian, V., Stefanovski, D., & Bergman, R. N. (2009) · Diabetes · doi:10.2337/db08-0875 · Cited by 43
Hauber, A., & Gale, E. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0108-0 · Cited by 44
Gao, Z., Bai, G., Chen, J., Zhang, Q., Pan, P., Bai, F., & Peng, G. E. N. G. (2009) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.80742 · Cited by 42
Functional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 42
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Why diabetes patients are more prone to the development of colon cancer?
Jin, T. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.03.025 · Cited by 41
Larsen, P. J., Wulff, E. M., Gotfredsen, C. F., Brand, C. L., Sturis, J., Vrang, N., Knudsen, L. B., & Lykkegaard, K. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00865.x · Cited by 36
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
Metadata
- Authors
- Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, J. J.
- ORCID
- Holst, J. J.
- Venue
- Diabetologia
- Published
- 2006-01-14
- Volume
- 49
- Issue
- 2
- Pages
- 253-260
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2082032596
- Cited by
- 228
- References
- 95
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 5 · 2019: 6 · 2018: 6 · 2017: 5 · 2016: 10 · 2015: 13 · 2014: 7 · 2013: 13 · 2012: 16
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- European Foundation for the Study of Diabetes
- Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, incretins, glucose-dependent insulinotropic polypeptide, proglucagon, type 2 diabetes, insulin secretion, incretin mimetics, DPP-4 inhibitors, dipeptidyl peptidase IV, HbA1c, weight loss, oral antidiabetic drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Insulin Secretion, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Intestines, Peptides, Protease Inhibitors, Venoms, Receptors, Glucagon, Dipeptidyl Peptidase 4, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.